content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 17, 2003
                                                           ----------------
  
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                   000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction   (Commission File Number)        (IRS Employer
       of Incorporation)                                       Identification No.)
  
  
  650 College Road East, 3rd Floor, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
  
  
                                   (609) 750-8200
                         -----------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
       Item 5.     Other Events and Required FD Disclosure.
  
  Product Update
  
  On January 17, 2003,  Cytogen  Corporation  (the  "Company")  and DRAXIMAGE Inc.
  ("DRAXIMAGE"), the radiopharmaceutical subsidiary of DRAXIS Health Inc., jointly
  issued a press release  reporting that the production and sales of the Palladium
  version of BrachySeed(TM) have been halted for an unspecified period of time.
  Production and sales of the Iodine-125 version of BrachySeed are continuing
  unchanged.
  
  BrachySeed Pd-103 was launched  commercially by Cytogen in May 2002 and is still
  in its early launch phase.  Cytogen and DRAXIMAGE are discussing ways to resolve
  issues surrounding Palladium BrachySeed production and sales.
  
  In December  2000,  Cytogen  entered into a 10-year  agreement with DRAXIMAGE to
  market and  distribute  BrachySeed  Iodine and Palladium  implants in the United
  States for the treatment of prostate  cancer in exchange for a transfer price on
  seeds  sold  plus  royalties  on sales  and  certain  milestone  payments.  Both
  companies'  decision to enter the brachytherapy field together was predicated on
  the successful launch of both the Iodine and Palladium brachytherapy products.
  
  Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
  by reference.  The foregoing  description  of such press release is qualified in
  its entirety by reference to such document.
  
       Item 7.     Financial Statements, Pro Forma Financial Information and
                   Exhibits.
  
       (c)  Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company dated January 17, 2003
  
  
  <PAGE>
  
  
                                     SIGNATURES
                                     ----------
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
  
                                         Cytogen Corporation
  
  
  
                                         By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  
  Date:  January 17, 2003
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k011703.txt", "description": "FORM 8-K DATED JANUARY 17, 2003", "secsgml_size_bytes": 3930}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03518015"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 17, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                   000-14879                  222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction   (Commission File Number)        (IRS Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, 3rd Floor, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
                                   (609) 750-8200
                         -----------------------------------
                           (Registrant's telephone number,
                                including area code)
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.     Other Events and Required FD Disclosure.
  
  Product Update
  
  On January 17, 2003,  Cytogen  Corporation  (the  "Company")  and DRAXIMAGE Inc.
  ("DRAXIMAGE"), the radiopharmaceutical subsidiary of DRAXIS Health Inc., jointly
  issued a press release  reporting that the production and sales of the Palladium
  version of BrachySeed(TM) have been halted for an unspecified period of time.
  Production and sales of the Iodine-125 version of BrachySeed are continuing
  unchanged.
  
  BrachySeed Pd-103 was launched  commercially by Cytogen in May 2002 and is still
  in its early launch phase.  Cytogen and DRAXIMAGE are discussing ways to resolve
  issues surrounding Palladium BrachySeed production and sales.
  
  In December  2000,  Cytogen  entered into a 10-year  agreement with DRAXIMAGE to
  market and  distribute  BrachySeed  Iodine and Palladium  implants in the United
  States for the treatment of prostate  cancer in exchange for a transfer price on
  seeds  sold  plus  royalties  on sales  and  certain  milestone  payments.  Both
  companies'  decision to enter the brachytherapy field together was predicated on
  the successful launch of both the Iodine and Palladium brachytherapy products.
  
  Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
  by reference.  The foregoing  description  of such press release is qualified in
  its entirety by reference to such document.
  
       Item 7.     Financial Statements, Pro Forma Financial Information and
                   Exhibits.
  
       (c)  Exhibits.
  
                Exhibit No.    Description
                -----------    -----------
                   99.1        Press release of the Company dated January 17, 2003
  SIGNATURES
                                     ----------
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                         Cytogen Corporation
  
                                         By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Date:  January 17, 2003